Key highlights
2025 DARZALEX Sales Overview
Genmab A/S announced that the worldwide net sales of DARZALEX® (daratumumab) reached USD 14,351 million in 2025. This figure includes sales of both the intravenous and subcutaneous (SC) products, with the latter sold under the tradename DARZALEX FASPRO® in the U.S.
Regional Sales Breakdown
In the United States, DARZALEX sales amounted to USD 8,266 million. The rest of the world contributed USD 6,085 million to the total sales figure.
Royalty Agreement
Genmab receives royalties on the worldwide net sales of DARZALEX from Johnson & Johnson (J&J), under an exclusive license agreement. This agreement allows J&J to develop, manufacture, and commercialize daratumumab globally.
